From First Session to Long-Term Maintenance: A Complete Guide to the Spravato Treatment Protocol at Allied Healthcare in North Canton, Ohio

For adults living with treatment-resistant depression, finding an effective path forward can feel overwhelming. Traditional antidepressants work well for many people, but roughly 30% of those diagnosed with major depressive disorder do not experience adequate relief after trying two or more medications. Spravato (esketamine nasal spray) was developed specifically for this population, and in 2026, it remains one of the most significant FDA-approved advancements in depression care. If you have been searching for Spravato treatment in Columbus, Ohio, or anywhere else across the state, Allied Healthcare in North Canton provides a comprehensive, protocol-driven approach that guides patients from their very first session through long-term maintenance.

What Is Spravato and How Does It Work?

Spravato is the brand name for esketamine, a nasal spray derived from ketamine that received FDA approval in 2019 for the treatment of treatment-resistant depression (TRD) in adults. It also holds an indication for adults with major depressive disorder (MDD) who are experiencing acute suicidal ideation or behavior. Unlike conventional antidepressants that primarily target serotonin, norepinephrine, or dopamine pathways, Spravato works on the brain’s glutamate system-the most abundant excitatory neurotransmitter. This different mechanism of action is believed to help restore synaptic connections in brain areas affected by chronic depression.

One of the most notable aspects of Spravato is the speed at which some patients begin to notice changes. While traditional antidepressants often require four to eight weeks to take effect, many patients undergoing Spravato therapy have reported improvements within hours to days of their initial sessions. It is important to note that individual results vary, and Spravato is always prescribed alongside an oral antidepressant as part of a comprehensive treatment plan.

Who May Be a Candidate for Spravato?

Spravato is not a first-line treatment for depression. It is specifically indicated for two groups of adult patients:

• Adults diagnosed with treatment-resistant depression, defined as an inadequate response to at least two different antidepressant medications taken at adequate doses for an adequate duration
• Adults with major depressive disorder who are experiencing acute suicidal thoughts or behavior

Candidacy is determined through a thorough clinical evaluation. At Allied Healthcare, the treatment team reviews each patient’s full psychiatric history, medication trials, current symptoms, and overall health before recommending Spravato. Patients across Ohio who have been exploring Spravato treatment in Columbus, Ohio, and other regions often find that a consultation at Allied Healthcare provides the clarity they need to determine whether this therapy is right for them.

Conditions That May Affect Eligibility

Certain medical conditions, including uncontrolled hypertension, a history of aneurysmal vascular disease, or a history of intracerebral hemorrhage, may affect a patient’s eligibility. Patients should always disclose their complete medical history during the initial consultation so the clinical team can make a fully informed recommendation.

The Spravato Treatment Protocol: Phase by Phase

Spravato follows a structured, phased protocol that is consistent across all certified treatment centers. Allied Healthcare adheres closely to this evidence-based schedule, ensuring each patient receives care in alignment with FDA guidelines and current best practices in 2026.

Phase One: Induction (Weeks 1 Through 4)

The induction phase is the most intensive stage of the Spravato protocol. During this period, patients attend sessions twice per week, typically with at least a few days between appointments. The initial dose is generally 56 mg, which may be adjusted to 84 mg based on clinical response and tolerability. This frequent schedule allows the medication to build therapeutic momentum while giving the treatment team the opportunity to monitor progress closely.

For many patients, this is the phase where initial changes in mood, energy, or outlook may begin to emerge. However, it is essential to understand that not everyone responds on the same timeline. Some individuals notice shifts within the first week, while others may require the full induction period-or beyond-to observe meaningful improvement.

Phase Two: Extended Treatment (Weeks 5 Through 8)

After completing the induction phase, patients transition to once-weekly sessions during weeks five through eight. This step-down allows the clinical team to assess whether the therapeutic benefits achieved during induction are sustained at a reduced frequency. Dosage adjustments may continue during this phase based on individual response.

Phase Three: Long-Term Maintenance (Week 9 and Beyond)

Beginning at week nine, patients who have responded favorably to treatment typically move to a maintenance schedule of once weekly or once every two weeks. The specific frequency is individualized based on symptom stability, clinical assessments, and ongoing conversations between the patient and their provider at Allied Healthcare. Real-world data from 2026 suggests that the benefits of Spravato may persist for months, though continued treatment is often recommended to sustain symptom relief.

Long-term maintenance is a critical component of the Spravato protocol. Depression is a chronic condition for many individuals, and maintenance sessions help support the neurological changes initiated during the earlier treatment phases. Allied Healthcare works with each patient to develop a sustainable, personalized maintenance plan.

What to Expect During Each Session at Allied Healthcare

Every Spravato session at Allied Healthcare follows a standardized process designed for safety and comfort. Because Spravato is classified under a Risk Evaluation and Mitigation Strategy (REMS) program, it must be administered in a certified healthcare setting under direct clinical supervision. Patients cannot take the medication at home.

Before Administration

Upon arrival, vital signs including blood pressure are checked. Because Spravato can cause a temporary increase in blood pressure, patients with elevated readings may need to wait until their levels stabilize before proceeding. Patients are also advised to avoid eating for at least two hours and drinking liquids for at least 30 minutes before their appointment.

During Administration

The patient self-administers the nasal spray under the guidance of a clinical staff member. The process involves two or three devices depending on the prescribed dose. Administration typically takes just a few minutes, after which the patient rests comfortably in a supervised treatment area.

The Observation Period

Following administration, patients are monitored for a minimum of two hours. During this time, the treatment team observes for common side effects, which may include dizziness, nausea, dissociation, sedation, or a temporary sense of detachment. These effects are typically mild to moderate and resolve within the observation window. Patients should not drive or operate heavy machinery for the remainder of the day after treatment, so arranging transportation in advance is required.

Why Patients Across Ohio Choose Allied Healthcare in North Canton

Allied Healthcare has established itself as a trusted provider of Spravato services in the North Canton and greater Canton area. The clinic’s commitment to a structured, patient-centered approach has made it a destination for individuals throughout Ohio who are seeking relief from treatment-resistant depression. Many patients who begin their search for Spravato treatment in Columbus, Ohio, or other metropolitan areas ultimately choose Allied Healthcare for its experienced clinical team and attentive care environment.

Insurance Coverage

Access to Spravato is supported by coverage from many major insurance carriers. Allied Healthcare accepts Aetna, Aultcare, Anthem, Blue Cross Blue Shield, Cigna, Medical Mutual of Ohio, United Healthcare/Oxford, and SummaCare for Spravato services. Patients are encouraged to contact Allied Healthcare directly to verify their specific plan’s participation.

A Growing Need in Ohio

In 2026, the demand for advanced depression treatments continues to grow across Ohio. With an estimated 1.2 million adults in the state experiencing depression annually and a significant percentage meeting the criteria for treatment resistance, access to FDA-approved therapies like Spravato is more important than ever. Allied Healthcare is positioned to serve patients in North Canton and from communities throughout the region who need specialized care that goes beyond traditional antidepressant therapy.

Taking the Next Step Toward Relief

Understanding the full Spravato treatment protocol-from the intensive induction phase through ongoing maintenance-can help patients feel more informed and confident as they consider this option. Whether you have been exploring Spravato treatment in Columbus, Ohio, or you are located closer to the Canton area, Allied Healthcare in North Canton offers a clear, well-structured path forward for individuals who have not found adequate relief from conventional antidepressants.

If you or someone you care about is living with treatment-resistant depression and would like to learn whether Spravato may be appropriate, Allied Healthcare welcomes you to schedule a consultation. Contact Allied Healthcare today to speak with a member of the clinical team, ask questions about the treatment process, and take the first step toward a personalized care plan.